Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians

Benzer Materyaller

• The widely promoted antimalarial drug hydroxychloroquine confers no mortality benefit in hospitalized patients with COVID-19: comment on the ‘Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19’
  Yazar:: Liuzzo, Giovanna, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• COVID 19: in the eye of the cytokine storm
  Yazar:: Liuzzo, Giovanna, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Conflicting results on the efficacy of remdesivir in hospitalized Covid-19 patients: comment on the Adaptive Covid-19 Treatment Trial
  Yazar:: Galiuto, Leonarda, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19
  Yazar:: Volpe, Massimo, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Regulating drugs, medical devices, and diagnostic tests in the European Union: early lessons from the COVID-19 pandemic?
  Yazar:: Fraser, Alan G, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)